{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:23:10Z","timestamp":1793751790410,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ajo.2025.12.015","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:07:56Z","timestamp":1766246876000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6870-0941","authenticated-orcid":false,"given":"Mya","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-817X","authenticated-orcid":false,"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-0660","authenticated-orcid":false,"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2025.12.015_bib0001","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.015_bib0006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/dmrr.2501","article-title":"Incretins: their physiology and application in the treatment of diabetes mellitus","volume":"30","author":"Tasyurek","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.015_bib0007","first-page":"1","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.015_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.015_bib0009","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: first Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.015_bib0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycemic control and body-weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajo.2025.12.015_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1032199","article-title":"Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data","volume":"13","author":"Dong","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ajo.2025.12.015_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2025.100186","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","author":"Scott Butsch","year":"2025","journal-title":"Obesity Pillars"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-025-03760-7","article-title":"Blinded by the drug? A vigilyze signal linking semaglutide to NAION","volume":"45","author":"Suresh","year":"2025","journal-title":"Int Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.015_bib0015","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide-1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ajo.2025.12.015_bib0016","series-title":"Semaglutide for managing overweight and obesity: recommendations","year":"2023"},{"key":"10.1016\/j.ajo.2025.12.015_bib0019","author":"Stewart"},{"key":"10.1016\/j.ajo.2025.12.015_bib0028","author":"Lilly"},{"key":"10.1016\/j.ajo.2025.12.015_bib0034","author":"Stewart"},{"key":"10.1016\/j.ajo.2025.12.015_bib0036","unstructured":"Food and Drug Administration. Qlik Sense. Accessed September 26, 2025. https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/33a0f68e-845c-48e2-bc81-8141c6aaf772\/state\/analysis."},{"key":"10.1016\/j.ajo.2025.12.015_bib0039","doi-asserted-by":"crossref","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2025.12.015_bib0041","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.015_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.015_bib0044","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ophtha.2007.05.027","article-title":"Nonarteritic anterior ischemic optic neuropathy","volume":"115","author":"Hayreh","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.015_bib0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.preteyeres.2011.02.003","article-title":"Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models","volume":"30","author":"Bernstein","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"10.1016\/j.ajo.2025.12.015_bib0046","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human Eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ajo.2025.12.015_bib0048","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1111\/dom.70107","article-title":"Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro","volume":"27","author":"Cheng","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.015_bib0051","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide, a dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: a Cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ajo.2025.12.015_sbref2052","series-title":"Monitoring Report: GLP-1 RA Prescribing Trends \u2013 December 2024 Data. medRxiv [preprint]","author":"Gratzl","year":"2025"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.015_bib0053","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal analysis of obesity drug use and public awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.015_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100547","article-title":"The Effect of GLP-1 receptor agonists on diabetic retinopathy at a tertiary care center","volume":"4","author":"Joo","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.015_bib0055","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.12.015_bib0056","article-title":"Ischemic optic neuropathy: what it is, symptoms & treatment","author":"Cleveland Clinic","year":"2023","journal-title":"Cleveland Clinic"},{"key":"10.1016\/j.ajo.2025.12.015_bib0057","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large-scale meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.015_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101664","article-title":"What the diabetologist needs to know about the risk of non-arteritic anterior ischemic optic neuropathy and glp-1 receptor agonist use in patients with type 2 diabetes","volume":"51","author":"Feldman-Billard","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ajo.2025.12.015_bib0059","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.015_bib0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.12.015_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500666X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942500666X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:13:27Z","timestamp":1781788407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942500666X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"alternative-id":["S000293942500666X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.015","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}